SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-003843
Filing Date
2022-03-16
Accepted
2022-03-16 08:30:28
Documents
13
Period of Report
2022-03-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K virx-20220316.htm   iXBRL 8-K 50900
2 EX-99.1 virx-ex99_1.htm EX-99.1 232024
  Complete submission text file 0000950170-22-003843.txt   412581

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT virx-20220316_lab.xml EX-101.LAB 12890
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT virx-20220316.xsd EX-101.SCH 2480
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT virx-20220316_pre.xml EX-101.PRE 9535
7 EXTRACTED XBRL INSTANCE DOCUMENT virx-20220316_htm.xml XML 4545
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 22743383
SIC: 2834 Pharmaceutical Preparations